Overview

Decitabine, Cytarabine, GCSF for Refractory AML/MDS

Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study will determine the activity of decitabine, low dose cytarabine (ARA-C) and G-CSF for patients with myelodysplasia and leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Brown University
Collaborators:
Memorial Hospital of Rhode Island
Roger Williams Medical Center
Treatments:
Cytarabine
Decitabine